PresentationPresentation Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Children with Relapsed or Refractory Leukemia PDF (608.60 KB) Read MorePresentation Selinexor, a Selective Inhibitor of Nuclear Export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma PDF (3.47 MB) Read MorePresentation ALS/FTD C9ORF72 hexanucleotide repeat expansion disrupts nucleocytoplasmic transport PDF (8.82 MB) Read MorePresentation Nuclear pore abnormalities in C9ORF72 ALS iPSC neurons and tissue alter nucleocytoplasmic protein trafficking PDF (9.64 MB) Read MorePresentation The role of nuclear export in TDP43-mediated neurodegeneration PDF (6.41 MB) Read MorePresentation Targeting CRM1 in AML (Presented at ESH – Budapest) PDF (2.52 MB) Read MorePresentation Selinexor Shows Marked Activity in Double-hit Diffuse Large B Cell Lymphoma (DLBCL) in Pre-clinical Models and in Patients with Heavily Pre-treated Relapsed/Refractory Double-hit DLBCL PDF (2.66 MB) Read MorePresentation Preliminary Phase II Results of Ara-C and Idarubicin in Combination with Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML PDF (296.65 KB) Read MorePresentation Patients with Heavily Pretreated Diffuse Large B-Cell Lymphoma (DLBCL) Who Respond to Oral Selinexor Therapy Show Prolonged Survival: Updated Phase I Results PDF (2.54 MB) Read MorePresentation A Phase 2 Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) PDF (1.30 MB) Read More Previous 1 … 7 8 9 10 11 … 15 Next